Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.

Hawaii medical journal ·Vol. 61 ·No. 3 ·2002-03-00 ·Pages 48, 57

Sarasombath P, Sumida K, Kaku DA

Abstract

A 79 year-old man was treated with Interferon alpha for chronic myelogenous leukemia and developed severe parkinsonism that resolved after Interferon alpha was stopped. Carbidopa-levodopa was associated with early improvement, but discontinuation did not result in worsening of the parkinsonism.

MeSH Terms

Aged Antineoplastic Agents/administration & dosage,adverse effects Antiparkinson Agents/administration & dosage Carbidopa/administration & dosage Humans Interferon alpha-2 Interferon-alpha/administration & dosage,adverse effects Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy Levodopa/administration & dosage Male Parkinson Disease, Secondary/chemically induced,drug therapy Recombinant Proteins Treatment Outcome

Chemicals

Antineoplastic Agents Antiparkinson Agents Interferon alpha-2 Interferon-alpha Recombinant Proteins Levodopa Carbidopa

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Sarasombath Pichaya

UH School of Medicine, 1356 Lusitana St., 7th Fl., Honolulu, HI 96813, USA. [email protected]

Sumida Kenneth

Kaku David A

Article Info

Journal

Hawaii medical journal

Abbr.

Hawaii Med J

ISSN

0017-8594

[email protected]

Published

2002-03-00

Pages

48, 57

Language

English

Region

United States

NLM ID

2984209R

Subset

External Links

PubMed source

Analysis Services

Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.

Contact

WeChat Official Account